Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

“We are thrilled with Wave Life Sciences commitment to the Alpha-1 patient community. Their acceleration of regulatory engagement of the […]

Read More… from Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

PRESS RELEASE SOMERVILLE, Mass., January 12, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic […]

Read More… from Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

Alpha-1 Global Meeting held in Argentina 

The second Latin American Alfa-1 Meeting titled “Consolidando avances, ampliando horizontes”, (“Consolidating Advances, Expanding Horizons”) was held on December 10, 2025, in Buenos Aires, Argentina.  Organized by Alfa1 Argentina and supported by […]

Read More… from Alpha-1 Global Meeting held in Argentina 

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial

“Thank you to the Alpha-1 patients that participated in this important clinical trial, InnovAATe. It is because of the dedication of patients […]

Read More… from Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial

University of Kentucky officially designated as a Clinical Resource Center (CRC) by A1F

Last month, the University of Kentucky was officially designated as a Clinical Resource Center (CRC) by the Alpha-1 Foundation. Alpha-1 […]

Read More… from University of Kentucky officially designated as a Clinical Resource Center (CRC) by A1F